• Nirali Patel, Shanice A McKenzie, Christina L Harview, Allison K Truong, Vivian Y Shi, Lucia Chen, Tristan R Grogan, Richard G Bennett, and Jennifer L Hsiao.
• Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
• J Dermatolog Treat. 2021 Jun 1; 32 (4): 473-475.

ObjectiveIsotretinoin has been used off-label in hidradenitis suppurativa (HS) patients with variable results, making it difficult to predict which patients with HS are likely to benefit.Material And MethodsWe conducted a retrospective review of HS patients who presented to UCLA HS clinic between August 2009 and March 2018 and collected data on their demographics, reported history of isotretinoin treatment for HS, and treatment response. A number of patient variables were analyzed between the responders and non-responders to see if any were associated with a higher likelihood of a beneficial response.ResultsOf the 209 patients, 39 (18.7%) reported prior treatment with isotretinoin. A beneficial response to isotretinoin was reported by 14 (35.9%) patients, while 25 (64.1%) patients reported no response. When comparing responders to non-responders, responders were more likely to have a history of pilonidal cyst (p = .024). Having a concomitant history of regular or cystic acne did not appear to enhance HS treatment response to isotretinoin.ConclusionsOur data suggest that for HS patients, having a history of pilonidal cyst is associated with a beneficial response to isotretinoin.

16 keywords...

hide…